Abstract:The cellular prion protein, PrP C , has been postulated to function as a receptor for α-synuclein, potentially facilitating cell-to-cell spreading and/or toxicity of α-synuclein aggregates in neurodegenerative disorders such as Parkinson's disease. Previously, we generated the "Salt (S)" and "No Salt (NS)" strains of α-synuclein aggregates that cause distinct pathological phenotypes in M83 transgenic mice overexpressing A53T-mutant human α-synuclein. To test the hypothesis that PrP C facilitates the propagation of α-synuclein aggregates, we produced M83 mice that either express or do not express PrP C . Following intracerebral inoculation with the S or NS strain, the absence of PrP C in M83 mice did not prevent disease development and had minimal influence on α-synuclein strain-specified attributes such as the extent of cerebral α-synuclein deposition, selective targeting of specific brain regions and cell types, the morphology of induced α-synuclein deposits, and the structural fingerprints of protease-resistant α-synuclein aggregates. Likewise, there were no appreciable differences in disease manifestation between PrP C -expressing and PrP C -lacking M83 mice following intraperitoneal inoculation of the S strain. Interestingly, intraperitoneal inoculation with the NS strain resulted in two distinct disease phenotypes, indicative of α-synuclein strain evolution, but this was also independent of PrP C expression. Overall, these results suggest that PrP C plays at most a minor role in the propagation, neuroinvasion, and evolution of α-synuclein strains in mice that express A53T-mutant human α-synuclein. Thus, other putative receptors or cell-to-cell propagation mechanisms may have a larger effect on the spread of α-synuclein aggregates during disease. During Parkinson's disease and related neurodegenerative disorders, the protein α-synuclein clumps together in the brain to form aggregates. α-Synuclein aggregates can spread between cells, and this process is believed to underlie disease progression. Thus, blocking the spread of α-synuclein aggregates may be a good therapeutic strategy for preventing the progression of Parkinson's disease. The details of how α-synuclein aggregates spread from cell to cell in the brain remain unclear, but it has been proposed that the cellular prion protein (PrP C ) may facilitate spreading by acting as a receptor for α-synuclein aggregates. However, this notion remains controversial. In this study, we compared the spread of α-synuclein aggregates within and to the brain in mice that either possessed or lacked PrP C . We found that the spreading of α-synuclein aggregates was largely independent of the presence of PrP C . This suggests that PrP C may not be an effective therapeutic target for attenuating the spread of α-synuclein aggregates in Parkinson's disease.

Blood-Derived α-Synuclein Aggregated in the Substantia Nigra of Parabiotic Mice

Evaluation of blood flow as a route for propagation in experimental synucleinopathy

The Spreading and Effects of Human Recombinant {alpha}-Synuclein Preformed Fibrils in the Cerebrospinal Fluid of Mice

AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease

Microglia affect α-synuclein cell-to-cell transfer in a mouse model of Parkinson's disease

Genomic DNA Levels of Mutant Alpha-Synuclein Correlate with Non-Motor Symptoms in an A53T Parkinson's Disease Mouse Model

Microglia affect α-synuclein cell-to-cell transfer in a mouse model of Parkinson’s disease

Cell-to-cell transmitted alpha-synuclein recapitulates experimental Parkinson’s disease

Aldh1a1 and additional markers of dopamine cell heterogeneity in substantia nigra and ventral tegmental area identified as preserved in two transgenic α-synuclein mouse models of neurodegenerative disease

Neuropathology in Mice Expressing Human Alpha-Synuclein.

Low-density lipoprotein receptor-related protein 1 mediates α-synuclein transmission from the striatum to the substantia nigra in animal models of Parkinson's disease

Viral overexpression of human alpha-synuclein in mouse substantia nigra dopamine neurons results in hyperdopaminergia but no neurodegeneration

Neither alpha-synuclein-preformed fibrils derived from patients with GBA1 mutations nor the host murine genotype significantly influence seeding efficacy in the mouse olfactory bulb

α-Synuclein strain propagation is independent of cellular prion protein expression in a transgenic synucleinopathy mouse model

The Synergistic Effect Study of Lipopolysaccharide (LPS) and A53T-α-Synuclein: Intranasal LPS Exposure on the A53T-α-Synuclein Transgenic Mouse Model of Parkinson's Disease

Neither alpha-synuclein fibril strain nor host murine genotype influences seeding efficacy

Mice Expressing A53T/A30P Mutant Alpha-Synuclein in Dopamine Neurons Do Not Display Behavioral Deficits

Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease

Establishment of Α-Synuclein Transgenic Mouse Model of Parkinson's Disease

Alpha‐synuclein fibrils amplified from multiple system atrophy and Parkinson's disease patient brain spread after intracerebral injection into mouse brain

Unique seeding profiles and prion-like propagation of synucleinopathies are highly dependent on the host in human α-synuclein transgenic mice